By John Harbison|2019-06-25T09:54:38-08:00June 12, 2019|Tech Coast Angels Portfolio Companies in the Press|Comments Off on Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)
